305 related articles for article (PubMed ID: 28085013)
1. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC.
Hu J; Li C; Liu C; Zhao S; Wang Y; Fu Z
Cancer Biomark; 2017; 18(1):87-94. PubMed ID: 28085013
[TBL] [Abstract][Full Text] [Related]
2. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
3. Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma.
Sun M; Fang S; Li W; Li C; Wang L; Wang F; Wang Y
Cancer Biomark; 2015; 15(1):33-40. PubMed ID: 25524940
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
Lee JC; Zhao JT; Clifton-Bligh RJ; Gill A; Gundara JS; Ip JC; Glover A; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB
Cancer; 2013 Dec; 119(24):4358-65. PubMed ID: 24301304
[TBL] [Abstract][Full Text] [Related]
6. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
7. Expression Levels of miR-30a-5p in Papillary Thyroid Carcinoma: A Comparison Between Serum and Fine Needle Aspiration Biopsy Samples.
Igci YZ; Ozkaya M; Korkmaz H; Bozgeyik E; Bayraktar R; Ulasli M; Erkilic S; Eraydin A; Oztuzcu S
Genet Test Mol Biomarkers; 2015 Aug; 19(8):418-23. PubMed ID: 26047355
[TBL] [Abstract][Full Text] [Related]
8. The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma.
Zhao Y; Liu X; Zhong L; He M; Chen S; Wang T; Ma S
Int J Mol Med; 2015 Oct; 36(4):1097-103. PubMed ID: 26252081
[TBL] [Abstract][Full Text] [Related]
9. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study.
Qiu ZL; Shen CT; Song HJ; Wei WJ; Luo QY
Nucl Med Biol; 2015 May; 42(5):499-504. PubMed ID: 25682061
[TBL] [Abstract][Full Text] [Related]
10. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
11. Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma.
Peng Y; Li C; Luo DC; Ding JW; Zhang W; Pan G
Molecules; 2014 Aug; 19(8):11586-99. PubMed ID: 25100252
[TBL] [Abstract][Full Text] [Related]
12. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of MiR-431 expression associated with lymph node metastasis and promotes cell invasion in papillary thyroid carcinoma.
Liu Y; Li L; Liu Z; Yuan Q; Lu X
Cancer Biomark; 2018; 22(4):727-732. PubMed ID: 29945344
[TBL] [Abstract][Full Text] [Related]
14. Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
Li M; Song Q; Li H; Lou Y; Wang L
PLoS One; 2015; 10(7):e0132403. PubMed ID: 26168287
[TBL] [Abstract][Full Text] [Related]
15. [Expression of microRNA-155 in papillary thyroid carcinoma and its clinical significance].
Zhu YZ; Zheng K; Zhang HH; Chen L; Wu KL; Ren CH; Wang ZC; Kong LJ; Ruan WH; Chen XJ
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Oct; 36(10):1364-1368. PubMed ID: 27777199
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of serum E-cadherin in patients with papillary thyroid carcinoma].
Sun L; Wang DM; Zhang WJ; Zhang J; Wu JF
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jan; 31(2):123-126. PubMed ID: 29871201
[No Abstract] [Full Text] [Related]
17. Disparity expression of gammaH2AX in papillary thyroid cancer and nodular goiter.
Hu S; Zhang G; Xu J; Zhu X; Lu X; Jiang L; Wang Q; Hou X; Cao J; Ge M
Clin Lab; 2014; 60(12):2031-7. PubMed ID: 25651738
[TBL] [Abstract][Full Text] [Related]
18. Different Expression of Erythrocyte Sedimentation Rate and C-reactive Protein in Papillary Thyroid Carcinoma and Nodular Goiter.
Hou X; Jiang L; Chen C; Zhu X; Ge M
Clin Lab; 2015; 61(7):793-9. PubMed ID: 26299079
[TBL] [Abstract][Full Text] [Related]
19. Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.
Graham ME; Hart RD; Douglas S; Makki FM; Pinto D; Butler AL; Bullock M; Rigby MH; Trites JR; Taylor SM; Singh R
J Otolaryngol Head Neck Surg; 2015 Sep; 44(1):33. PubMed ID: 26341226
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.
Yu S; Liu X; Zhang Y; Li J; Chen S; Zheng H; Reng R; Zhang C; Chen J; Chen L
Oncotarget; 2016 Dec; 7(51):84165-84177. PubMed ID: 27705935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]